便微生物种植与万科米辛治疗初级Clostridioides difficile感染:一个随机对照试验
Frederik Emil Juul1, Michael Bretthauer2, Peter H Johnsen3
1Clinical Effectiveness Research Group, Oslo University Hospital, Oslo, Norway; Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway; and Vestre Viken Bærum Hospital, Gjettum, Norway (F.E.J.).
Annals of internal medicine
|June 16, 2025
概括
便微生物种移植 (FMT) 显示出作为一线治疗初级Clostridioides difficile感染 (CDI) 的前途,显示出与标准万科米辛治疗相比的有效性和安全性. 这项研究表明,FMT可能是初始CDI管理的可行替代方案.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 微生物组研究 微生物组研究
背景情况:
- 便微生物种移植 (FMT) 是对复发性Clostridioides difficile感染 (CDI) 的推治疗方法.
- 对于初级 (初始) CDI 的 FMT 的疗效和安全性尚未得到充分证实.
- 这项研究旨在澄清FMT在治疗首次CDI发作患者中的作用.
研究的目的:
- 调查FMT作为一线治疗原发性Clostridioides difficile感染 (CDI) 的疗效和安全性.
- 为了比较没有抗生素预治疗的FMT与初级CDI的标准口服万科米辛治疗.
- 确定FMT是否与万科米辛相比,在实现临床治愈和预防初级CDI复发方面不劣.
主要方法:
- 进行了一项随机的,开放的,多中心的非劣势性试验,涉及被诊断为初级CDI的成年患者.
- 参与者被分配在没有抗生素预治疗的情况下接受FMT或口服万科迈辛10天.
- 主要终点是临床治愈,定义为坚固的便或14日每天不到三次排便,60天内没有疾病复发,只使用指定的治疗.
主要成果:
- 在104名随机选择的患者中,分析了100名. 在没有额外治疗的情况下,在60天内发生的临床治愈和没有复发的情况发生在66.7%的FMT组,而科米辛组的这一比例为61.2%.
- 在初级CDI治疗中,FMT被发现与万科米辛无差 (P为非劣势<0.001).
- 当考虑使用或不使用额外疗法的治疗时,FMT显示了较高的治愈率 (78.4%),而不是万科米辛 (61.2%),两组之间的不良事件没有显著差异.
结论:
- 便微生物群移植 (FMT) 可能被视为一线治疗患者的初级Clostridioides difficile感染 (CDI).
- 研究结果支持使用FMT作为一种有效和安全的替代品,用于初始CDI治疗.
- 进一步的研究可能会探索FMT在初级CDI中的最佳方案和长期结果.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
315
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
315
01:29Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
01:21Drugs for Treatment of Constipation-Predominant IBS
353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
207
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
207
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212